Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

Autor: Janet E Brown, Kara-Louise Royle, Walter Gregory, Christy Ralph, Anthony Maraveyas, Omar Din, Timothy Eisen, Paul Nathan, Tom Powles, Richard Griffiths, Robert Jones, Naveen Vasudev, Matthew Wheater, Abdel Hamid, Tom Waddell, Rhona McMenemin, Poulam Patel, James Larkin, Guy Faust, Adam Martin, Jayne Swain, Janine Bestall, Christopher McCabe, David Meads, Vicky Goh, Tze Min Wah, Julia Brown, Jenny Hewison, Peter Selby, Fiona Collinson, Judith Carser, Gopalakrishnan Srinivasan, Fiona Thistlewaite, Ashraf Azzabi, Mark Beresford, David Farrugia, Marios Decatris, Carys Thomas, Joanna Gale, James McAleer, Alison Clayton, Ekaterini Boleti, Thomas Geldart, Santhanam Sundar, Jason Lester, Nachi Palaniappan, Mohan Hingorani, Khaliq Rehman, Mohammad Khan, Naveed Sarwar, Janine Graham, Alastair Thomson, Narayanan Srihari, Denise Sheehan, Rajaguru Srinivasan, Omar Khan, Andrew Stockdale Jane Worlding, Stergios Boussios, Nicholas Stuart, Carey MacDonald-Smith, Falalu Danwata, Duncan McLaren, Aravindhan Sundaramurthy, Anna Lydon, Sharon Beesley, Kathryn Lees, Mohini Varughese, Emma Gray, Angela Scott, Mark Baxter, Anna Mullard, Pasquale Innominato, Gaurav Kapur, Anil Kumar, Natalie Charnley, Caroline Manetta, Prabir Chakraborti, Prantik Das, Sarah Rudman, Henry Taylor, Christos Mikropoulos, Martin Highley, Dakshinamoorthy Muthukumar, Anjali Zarkar, Roy Vergis, Seshadri Sriprasad, Patryk Brulinski, Amanda Clarke, Richard Osbourne, Melanie Harvey, Renata Dega, Geoffrey Sparrow, Urmila Barthakur, Erica Beaumont, Agnieszka Michael, Emilio Porfiri, Faisal Azam, Ravi Kodavtiganti

Publikováno v: STAR Investigators, Brown, J E, Royle, K-L, Gregory, W, Ralph, C, Maraveyas, A, Din, O, Eisen, T, Nathan, P, Powles, T, Griffiths, R, Jones, R, Vasudev, N, Wheater, M, Hamid, A, Waddell, T, McMenemin, R, Patel, P, Larkin, J, Faust, G, Martin, A, Swain, J, Bestall, J, McCabe, C, Meads, D, Goh, V, Min Wah, T, Brown, J, Hewison, J, Selby, P & Collinson, F 2023, ' Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial ', Lancet Oncology, vol. 24, no. 3, pp. 213-227 . https://doi.org/10.1016/S1470-2045(22)00793-8

Temporary drug treatment cessation might alleviate toxicity without substantially compromising efficacy in patients with cancer. We aimed to determine if a tyrosine kinase inhibitor drug-free interval strategy was non-inferior to a conventional conti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a633cdaf72543d0ca87f46d23005d79
https://doi.org/10.1016/s1470-2045(22)00793-8

Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer –5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life

Autor: R. Pearson, J. Frew, Rhona McMenemin, S. Atkinson, D. Leaning, A. Burns, X.Y. Jiang, Ian Pedley, Ashraf Azzabi, S. Cumming

Publikováno v: Clinical Oncology. 32:e177-e187

Aims Real-world evidence of radium 223 (Ra-223) for the treatment of men with metastatic castration-resistant prostate cancer is emerging. In this prospective single-centre service evaluation, we report for the first time in the UK, real-world qualit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d475b18f854716d3590f88e741083c1a
https://doi.org/10.1016/j.clon.2020.05.002

Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial

Autor: Tim Eisen, Bhavna Oza, Joaquim Bellmunt, Axel Bex, Janet E. Brown, Mahesh K. B. Parmar, Martin R. Stockler, Richard Kaplan, Barry W. Hancock, Ian D. Davis, Gregers G. Hermann, James Larkin, Steven Joniau, A.W.S. Ritchie, Jim Barber, Rhona McMenemin, Lisa Pickering, Angela M. Meade, Paul Nathan, Eleni Frangou, Elizabeth Hodgkinson, Bernard Escudier, Grant D. Stewart, Benjamin Smith, Laurence Albiges

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(34)

PURPOSE SORCE is an international, randomized, double-blind, three-arm trial of sorafenib after surgical excision of primary renal cell carcinoma (RCC) found to be at intermediate or high risk of recurrence. PATIENTS AND METHODS We randomly assigned

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7048e7916526f23d7c7a4d1385f9c71d
https://pubmed.ncbi.nlm.nih.gov/33874729

Sequential chemotherapy followed by radical thoracic radiotherapy (50 Gy in 25 fractions) in limited stage small cell lung cancer

Autor: Jill Gardiner, Paula Mulvenna, Philip Atherton, Muhammad Shahid Iqbal, Sandeep Singhal, T. Simmons, Joseph Carlow, Helen Turnbull, Fiona McDonald, Josef Kovarik, Rhona McMenemin, Alastair Greystoke

Publikováno v: ecancermedicalscience

Introduction For limited stage small cell lung cancer (LS-SCLC) where concurrent chemoradiotherapy is inappropriate due to tumour bulk, co-morbidities or performance status, sequential treatment using chemotherapy followed by radiotherapy is the stan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e3605b545b0510e48a88830763d0c32
https://doi.org/10.3332/ecancer.2020.1019

VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland

Autor: Syed A. Hussain, Maria Vilarino-Varlela, Richard J. Jackson, Jeanette Lyons, Lisa Pickering, Jawaher Ansari, James D. Wylie, Robert Huddart, Derek G. Power, Nils O. Elander, Rhona McMenemin, Guy Faust, Seema Chauhan

Publikováno v: International Journal of Oncology

There is no standard of care in the UK or Ireland for second-line chemotherapy for patients with advanced transitional cell carcinoma (TCCU). Vinflunine is approved for TCCU patients who have failed a platinum-based regimen, and is standard of care i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47924a6420a2ba1c98a8088a85984a71
https://doi.org/10.3892/ijo.2017.3847